SG187917A1 - Fused triazoles for the treatment or prophylaxis of mild cognitive impairment - Google Patents
Fused triazoles for the treatment or prophylaxis of mild cognitive impairment Download PDFInfo
- Publication number
- SG187917A1 SG187917A1 SG2013012604A SG2013012604A SG187917A1 SG 187917 A1 SG187917 A1 SG 187917A1 SG 2013012604 A SG2013012604 A SG 2013012604A SG 2013012604 A SG2013012604 A SG 2013012604A SG 187917 A1 SG187917 A1 SG 187917A1
- Authority
- SG
- Singapore
- Prior art keywords
- optionally substituted
- compound
- group
- salt
- ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010197064 | 2010-09-02 | ||
| JP2011143548 | 2011-06-28 | ||
| PCT/JP2011/070419 WO2012029991A1 (en) | 2010-09-02 | 2011-09-01 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG187917A1 true SG187917A1 (en) | 2013-04-30 |
Family
ID=45094181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2013012604A SG187917A1 (en) | 2010-09-02 | 2011-09-01 | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US8822699B2 (enExample) |
| EP (1) | EP2611805A1 (enExample) |
| JP (1) | JP5871909B2 (enExample) |
| KR (1) | KR20130139895A (enExample) |
| CN (1) | CN103249733A (enExample) |
| AR (1) | AR082865A1 (enExample) |
| AU (1) | AU2011296887A1 (enExample) |
| BR (1) | BR112013004746A2 (enExample) |
| CA (1) | CA2809779A1 (enExample) |
| CL (1) | CL2013000575A1 (enExample) |
| DO (1) | DOP2013000051A (enExample) |
| EA (1) | EA201390333A1 (enExample) |
| EC (1) | ECSP13012535A (enExample) |
| MA (1) | MA34556B1 (enExample) |
| MX (1) | MX2013002511A (enExample) |
| PE (1) | PE20131305A1 (enExample) |
| PH (1) | PH12013500403A1 (enExample) |
| SG (1) | SG187917A1 (enExample) |
| TW (1) | TW201213327A (enExample) |
| UY (1) | UY33586A (enExample) |
| WO (1) | WO2012029991A1 (enExample) |
| ZA (1) | ZA201301929B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011007756A1 (ja) * | 2009-07-13 | 2011-01-20 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| WO2012029991A1 (en) * | 2010-09-02 | 2012-03-08 | Takeda Pharmaceutical Company Limited | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment |
| EP2687528A1 (en) * | 2012-07-17 | 2014-01-22 | Ares Trading S.A. | Fused triazole derivatives as gamma secretase modulators |
| RU2563254C2 (ru) * | 2013-07-08 | 2015-09-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина |
| AU2016259529B2 (en) * | 2015-05-12 | 2020-10-01 | Fmc Corporation | Aryl substituted bicyclic compounds as herbicides |
| US20210079182A1 (en) * | 2019-09-12 | 2021-03-18 | Dupont Electronics, Inc. | Polyimide films and electronic devices |
| JP2024546600A (ja) * | 2021-12-17 | 2024-12-26 | アティラ・ファーマ・インコーポレイテッド | 疾患の治療のための二環式化合物の使用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2395862A1 (en) | 2000-02-17 | 2001-08-23 | Hong Liu | Succinoylamino carbocycles and heterocycles as inhibitors of a.beta. protein production |
| WO2004110350A2 (en) | 2003-05-14 | 2004-12-23 | Torreypines Therapeutics, Inc. | Compouds and uses thereof in modulating amyloid beta |
| CA2539811A1 (en) * | 2003-10-15 | 2005-04-28 | Targacept, Inc. | Azabicycyclic compounds for relieving pain and treating central nervous system disorders |
| US7667041B2 (en) | 2004-05-26 | 2010-02-23 | Eisai R&D Management Co., Ltd. | Cinnamide compound |
| KR20070083781A (ko) | 2004-10-26 | 2007-08-24 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물의 비정질체 |
| US20090221611A1 (en) | 2006-01-11 | 2009-09-03 | Devita Robert J | Fused Triazole Tachykinin Receptor Antagonists |
| EA016464B1 (ru) * | 2006-03-09 | 2012-05-30 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Полициклические производные арилимидазола |
| TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
| TW200808800A (en) | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
| US8143394B2 (en) | 2006-12-26 | 2012-03-27 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
| EP2119719A1 (en) | 2006-12-26 | 2009-11-18 | Daiichi Sankyo Company, Limited | Thiazepine derivative |
| WO2008097538A1 (en) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Therapeutic agents |
| AU2008333865A1 (en) | 2007-12-06 | 2009-06-11 | Schering Corporation | Gamma secretase modulators |
| TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
| JP2010197064A (ja) | 2009-02-23 | 2010-09-09 | Chugoku Electric Power Co Inc:The | 直下位置測定装置 |
| RU2515976C2 (ru) | 2009-02-26 | 2014-05-20 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Азотсодержащие конденсированные гетероциклические соединения и их применение в качестве ингибиторов продукции бета-амилоида |
| JP2012051806A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
| JP2012051807A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | アリールイミダゾール化合物 |
| WO2011002067A1 (ja) | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2011007756A1 (ja) | 2009-07-13 | 2011-01-20 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| EA021047B1 (ru) | 2009-07-15 | 2015-03-31 | Янссен Фармасьютикалз, Инк. | Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TWI468402B (zh) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | 降低β-類澱粉生成之化合物 |
| WO2011016559A1 (ja) | 2009-08-07 | 2011-02-10 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| JP2011143548A (ja) | 2010-01-12 | 2011-07-28 | Panasonic Corp | スクリーン印刷機及びスクリーン印刷方法 |
| MX2012008260A (es) | 2010-01-15 | 2012-08-17 | Janssen Pharmaceuticals Inc | Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa. |
| WO2012029991A1 (en) * | 2010-09-02 | 2012-03-08 | Takeda Pharmaceutical Company Limited | Fused triazoles for the treatment or prophylaxis of mild cognitive impairment |
-
2011
- 2011-09-01 WO PCT/JP2011/070419 patent/WO2012029991A1/en not_active Ceased
- 2011-09-01 MA MA35785A patent/MA34556B1/fr unknown
- 2011-09-01 KR KR1020137008170A patent/KR20130139895A/ko not_active Withdrawn
- 2011-09-01 EA EA201390333A patent/EA201390333A1/ru unknown
- 2011-09-01 AR ARP110103195A patent/AR082865A1/es unknown
- 2011-09-01 BR BR112013004746A patent/BR112013004746A2/pt not_active IP Right Cessation
- 2011-09-01 EP EP11791058.8A patent/EP2611805A1/en not_active Withdrawn
- 2011-09-01 UY UY0001033586A patent/UY33586A/es unknown
- 2011-09-01 TW TW100131443A patent/TW201213327A/zh unknown
- 2011-09-01 MX MX2013002511A patent/MX2013002511A/es not_active Application Discontinuation
- 2011-09-01 CN CN2011800518621A patent/CN103249733A/zh active Pending
- 2011-09-01 SG SG2013012604A patent/SG187917A1/en unknown
- 2011-09-01 CA CA2809779A patent/CA2809779A1/en not_active Abandoned
- 2011-09-01 AU AU2011296887A patent/AU2011296887A1/en not_active Abandoned
- 2011-09-01 PE PE2013000360A patent/PE20131305A1/es not_active Application Discontinuation
- 2011-09-01 US US13/223,455 patent/US8822699B2/en not_active Expired - Fee Related
- 2011-09-01 US US13/819,239 patent/US8901309B2/en not_active Expired - Fee Related
- 2011-09-01 JP JP2013510386A patent/JP5871909B2/ja not_active Expired - Fee Related
- 2011-09-01 PH PH1/2013/500403A patent/PH12013500403A1/en unknown
-
2013
- 2013-02-28 CL CL2013000575A patent/CL2013000575A1/es unknown
- 2013-03-01 DO DO2013000051A patent/DOP2013000051A/es unknown
- 2013-03-14 ZA ZA2013/01929A patent/ZA201301929B/en unknown
- 2013-03-28 EC ECSP13012535 patent/ECSP13012535A/es unknown
-
2014
- 2014-08-08 US US14/454,993 patent/US20140350260A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120059030A1 (en) | 2012-03-08 |
| UY33586A (es) | 2012-03-30 |
| MA34556B1 (fr) | 2013-09-02 |
| ECSP13012535A (es) | 2013-06-28 |
| KR20130139895A (ko) | 2013-12-23 |
| EA201390333A1 (ru) | 2013-08-30 |
| ZA201301929B (en) | 2013-11-27 |
| CA2809779A1 (en) | 2012-03-08 |
| DOP2013000051A (es) | 2013-04-30 |
| BR112013004746A2 (pt) | 2016-06-07 |
| WO2012029991A1 (en) | 2012-03-08 |
| AR082865A1 (es) | 2013-01-16 |
| US20140350260A1 (en) | 2014-11-27 |
| CL2013000575A1 (es) | 2013-08-23 |
| MX2013002511A (es) | 2013-07-29 |
| EP2611805A1 (en) | 2013-07-10 |
| PH12013500403A1 (en) | 2013-03-25 |
| JP2013536798A (ja) | 2013-09-26 |
| TW201213327A (en) | 2012-04-01 |
| US8901309B2 (en) | 2014-12-02 |
| JP5871909B2 (ja) | 2016-03-01 |
| PE20131305A1 (es) | 2013-10-31 |
| US20130178497A1 (en) | 2013-07-11 |
| US8822699B2 (en) | 2014-09-02 |
| CN103249733A (zh) | 2013-08-14 |
| AU2011296887A1 (en) | 2013-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2763979T3 (en) | 1-arylcarbonyl-4-oxy-piperidine compounds for the treatment of neurodegenerative diseases | |
| ES2695350T3 (es) | Compuesto heterocíclico | |
| US9777005B2 (en) | Bicyclic heterocyclic compound containing a substituted pyrrole ring | |
| EP2982666B1 (en) | Heterocyclic compound | |
| US8822699B2 (en) | Heterocyclic compound and use thereof | |
| US20170129887A1 (en) | Nitrogenated heterocyclic compound | |
| JP5722781B2 (ja) | 縮合複素環誘導体およびその用途 | |
| EP2982670B1 (en) | Heterocyclic compound | |
| EP2604597A1 (en) | Heterocyclic compound and use thereof | |
| EP2597095A1 (en) | Fused heterocyclic compound and application thereof | |
| JPWO2009113560A1 (ja) | 縮合複素環化合物 | |
| JP5888702B2 (ja) | 抗癌活性化合物 | |
| WO2012008508A1 (ja) | 複素環化合物 | |
| JP2012136500A (ja) | 複素環化合物 | |
| WO2013005354A1 (ja) | 複素環化合物 | |
| JPWO2013100018A1 (ja) | 複素環化合物 | |
| HK1196368A (en) | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | |
| HK1196368B (en) | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases |